What retatrutide is
Retatrutide is the working name for LY3437943, an investigational peptide from Eli Lilly built on a single 39-residue backbone carrying a C18 fatty-acid chain. That acylation extends its plasma half-life to roughly six days, which is why the clinical program uses once-weekly dosing. What makes it unusual is not the scaffold but the receptor coverage: a single molecule that engages three metabolic receptors instead of one or two. It sits one step beyond the dual agonist tirzepatide, and the published data so far place it at the top of the incretin class for effect on body weight.
The triple-agonist mechanism, receptor by receptor
The reason retatrutide behaves differently from a GLP-1 drug comes down to which doors it opens. Think of the three receptors as three separate levers on the body’s energy budget — most peptides pull one, retatrutide pulls all three at the same time.
- GLP-1 receptor — the satiety and glucose-control lever, the same one semaglutide acts on. Slows gastric emptying and reduces food intake. Retatrutide binds it with low-nanomolar affinity (EC50 ~0.1 nM).
- GIP receptor — modulates insulin response and appears to buffer the nausea of pure GLP-1 activation, the same arm that distinguishes tirzepatide.
- Glucagon receptor — the differentiator. Activating it raises hepatic energy expenditure through lipid oxidation and thermogenesis, the spending side of the ledger rather than the appetite side. Neither semaglutide nor tirzepatide touches this receptor.
Coskun et al. (Cell Metabolism, 2022) characterised the binding ratios and showed the glucagon component drives up to an 80% drop in liver-fat content in mouse models — the preclinical signal behind the compound’s interest in hepatic steatosis research.
The NEJM Phase 2 data
The headline numbers come from Jastreboff et al., “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial,” published in the New England Journal of Medicine (2023). It was a randomized, double-blind, placebo-controlled study of 338 adults across 25 U.S. centers, run over 48 weeks.
| Compound | Receptors | Reported weight change | Source |
|---|---|---|---|
| Semaglutide | GLP-1 | ≈ −15 to −17% | STEP program |
| Tirzepatide | GLP-1 / GIP | ≈ −22.5% | SURMOUNT-1 |
| Retatrutide | GLP-1 / GIP / glucagon | −24.2% (48 wk) | NEJM 2023 |
Two details matter beyond the topline figure. First, speed: roughly −17.5% was reached by week 24, so the curve had not plateaued at the trial’s end. Second, the metabolic side-effects: post-hoc analysis reported lower triglycerides (≈ −30%), reduced systolic blood pressure (≈ −7 mmHg) and improved glycemic markers — consistent with the glucagon-driven shift in energy handling rather than appetite suppression alone.
The 2026 update: TRIUMPH-1 Phase 3
The Phase 2 figures above were the headline until May 2026, when Eli Lilly announced the first Phase 3 readout from the TRIUMPH program (TRIUMPH-1). The reported result was the largest weight reduction recorded in a Phase 3 obesity trial — pushing well beyond the −24.2% of the Phase 2 study and, in the higher-dose arm over the longer treatment window, into territory that puts a once-weekly injection in the same conversation as bariatric surgery. That announcement is what turned retatrutide from a specialist topic into the most-discussed metabolic molecule of the year.
The regulatory timeline, however, is slow: an NDA is expected in Q4 2026, FDA approval not before late 2027, and a commercial launch around 2028. So there is a multi-year gap between the data landing and the molecule reaching a pharmacy. We cover what that gap means for access and cost — and how it interacts with the 2026 GLP-1 compounding ban — in the NHS access and cost guide and the compounding-ban analysis. For the dual-agonist comparison readers ask about most, see retatrutide vs tirzepatide.
Dosing as it appears in the literature
The Phase 2 protocol used weekly subcutaneous arms of 1, 4, 8 and 12 mg, reached by slow titration from a low starting dose to limit gastrointestinal effects. These are the doses studied in a regulated clinical trial in human subjects — they describe the published research, not a protocol to follow. Research-grade retatrutide is a lyophilized reagent for in-vitro work and is never reconstituted for human use. For the concentration math involved in handling a lyophilized vial in a research model, the method in our reconstitution and dosage guide applies to any peptide: concentration = mass ÷ volume.
Where retatrutide sits in metabolic research
Retatrutide is the most-discussed member of a widening field. A parallel strategy — the amylin axis — is covered in our cagrilintide guide, while the next experimental step on the incretin side — adding PPAR activation — is in our quintuple-agonist analysis. For purity standards, storage and how to evaluate a Certificate of Analysis across the whole catalog, see the complete research peptides guide, and for supplier-level checks the retatrutide sourcing guide.